Targeting IGFBP2 MERTK PITPNC1 to Block Metastatic Angiogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for angiogenesis disorders, particularly metastatic cancer, are limited in effectively inhibiting pathological angiogenesis and metastasis, with existing VEGF inhibition methods showing limited success in preventing metastasis and new pathways for regulation remain understudied.
Innovation Solution
The method involves administering agents that inhibit the expression or activity of proteins such as IGFBP2, MERTK, and PITPNC1 to regulate endothelial recruitment and angiogenesis, using antibodies, nucleic acids, or small molecule compounds, and identifying specific gene expression levels to diagnose metastatic potential.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF inhibition is used to treat angiogenesis disorders, then tumor growth is suppressed, but metastasis prevention remains ineffective
Solution Approach 1:
The patent changes the molecular target parameter from VEGF to a combination of IGFBP2, MERTK, and PITPNC1 proteins. This parameter change enables effective metastasis prevention by blocking endothelial cell recruitment through alternative angiogenic pathways, thereby resolving the limitation of VEGF inhibition that failed to prevent metastasis in stage IV cancer
Solution Approach 2:
The patent segments the angiogenesis inhibition strategy into multiple independent targets: IGFBP2 (insulin-like growth factor binding protein 2), MERTK (mer tyrosine kinase), and PITPNC1 (phosphatidylinositol transfer protein). By targeting these separate molecular pathways simultaneously, the invention achieves comprehensive blockade of metastatic angiogenesis that cannot be accomplished by VEGF inhibition alone
2Reliability
If new regulatory pathways are targeted, then treatment efficacy for metastasis is improved, but treatment complexity increases
Solution Approach 1:
The patent merges multiple protein inhibition functions into a unified therapeutic approach. By combining anti-IGFBP2, anti-MERTK, and anti-PITPNC1 agents into a single treatment regimen, the invention achieves synergistic blockade of endothelial recruitment while managing complexity through coordinated multi-target therapy rather than separate sequential treatments
Solution Approach 2:
The patent develops universal therapeutic agents that can function across different metastatic contexts. The multi-protein inhibition approach serves multiple functions: blocking angiogenesis, preventing endothelial cell recruitment, and addressing molecular heterogeneity in metastatic cancer, thereby providing a versatile treatment that adapts to various cancer types and stages
Data Source
AI summary
This invention concerns pathological angiogenesis and cancer, related treatment methods, and related compositions. Also disclosed are related diagnosis kits and methods.